Takeuchi N, Nakamura T, Takeuchi F, Hashimoto E, Yamamura H
Department of Internal Medicine, Fukui Medical School.
J Biochem. 1992 Dec;112(6):762-7. doi: 10.1093/oxfordjournals.jbchem.a123972.
Mitoxantrone, a new anthraquinone, showed inhibitory an effect on protein kinase C (PKC) activity. Its IC50 value was 4.4 micrograms/ml (8.5 microM), which is much lower than those of the well-known anthracyclines daunorubicin and doxorubicin, the IC50 values of which are more than 100 micrograms/ml (> 170 microM). Kinetic studies demonstrated that mitoxantrone inhibited PKC in a competitive manner with respect to histone H1, and its Ki value was 6.3 microM (Ki values of daunorubicin and doxorubicin were 0.89 and 0.15 mM, respectively), and in a non-competitive manner with respect to phosphatidylserine and ATP. Inhibition of phosphorylation by mitoxantrone was observed with various substrates including S6 peptide, myelin basic protein and its peptide substrate derived from the amino-terminal region. Their IC50 values were 0.49 microgram/ml (0.95 microM), 1.8 micrograms/ml (3.5 microM), and 0.82 microgram/ml (1.6 microM), respectively. Mitoxantrone did not markedly inhibit the activity of cyclic AMP-dependent protein kinase, casein kinase I or casein kinase II, at concentrations of less than 10 micrograms/ml. On the other hand, brief exposure (5 min) of HL60 cells to mitoxantrone caused the inhibition of cell growth with an IC50 value of 52 ng/ml (0.1 microM). In HL60 cells, most of the PKC activity (about 90%) was detected in the cytosolic fraction. When HL60 cells exposed to 10 micrograms/ml mitoxantrone for 5 min were observed with fluorescence microscopy, the fluorescence elicited from mitoxantrone was detected in the extranuclear area. These results indicated that mitoxantrone is a potent inhibitor of PKC, and this inhibition may be one of the mechanisms of antitumor activity of mitoxantrone.
米托蒽醌是一种新型蒽醌,对蛋白激酶C(PKC)活性有抑制作用。其半数抑制浓度(IC50)值为4.4微克/毫升(8.5微摩尔),远低于著名的蒽环类药物柔红霉素和阿霉素,柔红霉素和阿霉素的IC50值超过100微克/毫升(>170微摩尔)。动力学研究表明,米托蒽醌对组蛋白H1而言以竞争性方式抑制PKC,其抑制常数(Ki)值为6.3微摩尔(柔红霉素和阿霉素的Ki值分别为0.89和0.15毫摩尔),而对磷脂酰丝氨酸和三磷酸腺苷(ATP)而言以非竞争性方式抑制。米托蒽醌对包括S6肽、髓鞘碱性蛋白及其氨基末端区域衍生的肽底物在内的多种底物的磷酸化均有抑制作用。它们的IC50值分别为0.49微克/毫升(0.95微摩尔)、1.8微克/毫升(3.5微摩尔)和0.82微克/毫升(1.6微摩尔)。在浓度低于10微克/毫升时,米托蒽醌不会显著抑制环磷酸腺苷(cAMP)依赖性蛋白激酶、酪蛋白激酶I或酪蛋白激酶II的活性。另一方面,HL60细胞短暂暴露(5分钟)于米托蒽醌会导致细胞生长受到抑制,IC50值为52纳克/毫升(0.1微摩尔)。在HL60细胞中,大部分PKC活性(约90%)在胞质部分检测到。当用荧光显微镜观察暴露于10微克/毫升米托蒽醌5分钟的HL60细胞时,在核外区域检测到米托蒽醌引发的荧光。这些结果表明米托蒽醌是一种有效的PKC抑制剂,这种抑制作用可能是米托蒽醌抗肿瘤活性的机制之一。